A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

doi:10.1126/science.abc2241

GSTDTAP > 气候变化

DOI	10.1126/science.abc2241
	A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
	Yan Wu; Feiran Wang; Chenguang Shen; Weiyu Peng; Delin Li; Cheng Zhao; Zhaohui Li; Shihua Li; Yuhai Bi; Yang Yang; Yuhuan Gong; Haixia Xiao; Zheng Fan; Shuguang Tan; Guizhen Wu; Wenjie Tan; Xuancheng Lu; Changfa Fan; Qihui Wang; Yingxia Liu; Chen Zhang; Jianxun Qi; George Fu Gao; Feng Gao; Lei Liu
	2020-06-12
发表期刊	Science
出版年	2020
英文摘要	One of the responses of the immune system to invading viruses is the production of antibodies. Some of these are neutralizing, meaning that they prevent the virus from being infectious, and can thus be used to treat viral diseases. Wu et al. isolated four neutralizing antibodies from a convalescent coronavirus disease 2019 (COVID-19) patient. Two of the antibodies, B38 and H4, blocked the receptor binding domain (RBD) of the viral spike protein from binding to the cellular receptor, angiotensin-converting enzyme 2 (ACE2). The structure of the RBD bound to B38 shows that the B38-binding site overlaps with the binding site for ACE2. Although H4 also blocks RBD binding to ACE2, it binds at a different site, and thus the two antibodies can bind simultaneously. This pair of antibodies could potentially be used together in clinical applications. Science , this issue p. [1274][1] Neutralizing antibodies could potentially be used as antivirals against the coronavirus disease 2019 (COVID-19) pandemic. Here, we report isolation of four human-origin monoclonal antibodies from a convalescent patient, all of which display neutralization abilities. The antibodies B38 and H4 block binding between the spike glycoprotein receptor binding domain (RBD) of the virus and the cellular receptor angiotensin-converting enzyme 2 (ACE2). A competition assay indicated different epitopes on the RBD for these two antibodies, making them a potentially promising virus-targeting monoclonal antibody pair for avoiding immune escape in future clinical applications. Moreover, a therapeutic study in a mouse model validated that these antibodies can reduce virus titers in infected lungs. The RBD-B38 complex structure revealed that most residues on the epitope overlap with the RBD-ACE2 binding interface, explaining the blocking effect and neutralizing capacity. Our results highlight the promise of antibody-based therapeutics and provide a structural basis for rational vaccine design. [1]: /lookup/doi/10.1126/science.abc2241
领域	气候变化 ; 资源环境
URL	查看原文
引用统计	被引频次：663[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://119.78.100.173/C666/handle/2XK7JSWQ/274477
专题	气候变化资源环境科学
推荐引用方式 GB/T 7714	Yan Wu,Feiran Wang,Chenguang Shen,et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2[J]. Science,2020.
APA	Yan Wu.,Feiran Wang.,Chenguang Shen.,Weiyu Peng.,Delin Li.,...&Lei Liu.(2020).A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2.Science.
MLA	Yan Wu,et al."A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2".Science (2020).